Masters Degrees (Physiological Sciences)

Permanent URI for this collection

https://scholar.sun.ac.za/handle/10019.1/3772

Browse

Browsing Masters Degrees (Physiological Sciences) by browse.metadata.advisor "Engelbrecht, A-M."

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Investigating the effects of diet-induced obesity on acute Doxorubicin-induced cardiotoxicity in a tumour-bearing model
    (Stellenbosch : Stellenbosch University, 2019-04) Bock, Bianca Annina; Sishi, Balindiwe J. N.; Engelbrecht, A-M.; Stellenbosch University. Faculty of Science. Dept. of Physiological Sciences.
    ENGLISH ABSTRACT: Introduction: Obesity is a well-known global pandemic that is fundamentally caused by an energy imbalance between calories consumed and calories expended. A major consequence to obesity are metabolic perturbations that are accompanied by insulin insensitivity and central obesity. Not only, but also are these factors associated with metabolic syndrome, they increase the risk of developing cardiovascular disease. Recently, obesity has been linked to the development of cancer, particularly breast and prostate cancer. While numerous mechanisms have been proposed, by far the biological mechanisms that has received much attention include insulin, insulin-like growth factor-1 (IGF-1), sex hormones and adipokines. While research on the mechanisms underlying obesity and its relationship with cancer are still in the early stages, understanding the processes of carcinogenesis in obesity-related cancers may lead to the development of treatments and better preventative strategies. Interestingly, the use of doxorubicin (DOX), a potent chemotherapeutic agent, is limited by its cumulative, dose- dependent toxicity that can lead to the development and progression of congestive heart failure. Considering that these inflammatory diseases have mainly been studied in isolation, there are very few, if any studies that have investigated cancer and cardiotoxicity in the context of obesity, to better understand the complex relationship that these diseases have with one another and how cardiovascular function is adversely affected in this scenario. Therefore, this study hypothesized that cancer in an obese environment increases the risk of developing early-stage DOX-induced cardiotoxicity. Methods: Three-week-old female C57BL6 mice were acclimatized and randomly placed on either a high (H) fat diet or standard (S) diet for eight weeks to induce obesity. After eight weeks on the diet, these groups were further divided into two more groups were half of the mice in S and in H groups were inoculated with EO771 breast cancer cells and the others were not (non-tumour control group). Once tumours were palpable, animals were divided into more groups were some received DOX treatment. Each animal on treatment received three intraperitoneal injections of 4 mg/kg DOX resulting in a cumulative dose of 12 mg/kg. Animals remained on their respective diets for the duration of the study and were monitored daily. Four days after the last injection, animals were weighted, euthanized and their hearts excised. The blood collected was used to analyse circulating cytokines, adipokines and other markers of cardiovascular damage, while heart tissue was preserved in formalin for histological staining, or snap frozen for biochemical analyses including oxidative stress and apoptosis. Results: Animals exposed to the high fat diet gained significantly more weight by the end of the study (29.24 ± 1.99 g, p<0.0001) versus those on the standard diet (19.72 ± 0.52 g). Not only did these animals display increased gonadal adiposity, circulating levels of glucose and leptin were also elevated. Furthermore, this group of animals showed a decreased heart-to-body weight ratio and fibrosis when compared to their control counter parts. In the presence of a tumour (T), there was a considerable decline in body weight in both diet groups (S+T and H+T) when compared to the diet groups (S and H) alone. This study also observed a decrease in body weight when group S+T was compared to group H+T. Interleukin-6 (IL-6) levels were significantly augmented in group H+T (64.95 ± 11.62 pg/ml, p<0.01) versus group H (24.17 ± 5.59 pg/ml). While no major histological changes were observed in the high fat diet fed animals (H and H+T), interstitial congestion within the heart tissue and reduced fibrosis was evident in the standard fed group with a tumour (1.23±0.20%, p<0.001) when compared to the standard diet fed animals alone (2.40 ± 0.23%). When DOX (D) treatment was introduced to animals that received either diet, the body weight of animals fed the high fat diet (H+D) (25.02 ± 0.84 g, p<0.001) remained significantly higher than the animals fed the standard diet in the presence of DOX (S+D) (19.05 ± 0.23 g). Moreover, body weight loss was also observed when the high fat diet alone group (H) (29.24 ± 1.99 g) was compared to the high fat diet animals with tumours and treated with DOX (H+T+D) (21.30 ± 1.25 g, p<0.0001). This group of animals (H+T+D) also displayed significantly decreased adiposity and leptin levels, however the IL-6 concentration was elevated (126.90 ± 34.92 pg/ml, p<0.05) when compared to group H alone (24.17 ± 5.59 pg/ml). There was no evidence of cardiovascular damage or apoptotic cell death. Discussion and Conclusion: It is clear from the results above that a diet high in fat contributes to the development of obesity and the dysregulation of adipokines inducing an inflammatory state. However, this inflammatory response did not have a major impact on cardiovascular health. When the complication of cancer arises in the context of obesity, the inflammatory state is aggravated due the rise in the pro-inflammatory cytokine IL-6. Although cancer is known to result in significant weight loss, in this context, the loss of weight, particularly fat mass may be initially viewed as beneficial. However if this loss of weight is sustained over an extended period of time, detrimental effects become evident. When DOX therapy was administered in this co-morbid state, it too contributed to the decrease in body weight, adiposity and leptin concentrations, while IL-6 levels remained elevated. It is therefore possible that the weight loss observed in this study may be attributed to the stimulation of degradation pathways as these pathways are known to be triggered by inflammation and also DOX. While this study did not demonstrate considerable alterations in myocardial tissue, possibly due to the model not being severe enough to induce such changes in a short period oftime, this study is the first to our knowledge to develop a co-morbid model of obesity and cancer with chemotherapy.